हिंदी में पढ़ें

Cipla

Cipla shares surge nearly 10% after positive USFDA update on Goa facility

Cipla shares surge nearly 10% after positive USFDA update on Goa facility

Thu, Oct 31, 2024

USFDA's VAI classification boosts Cipla’s outlook for niche drug launches, including Abraxane generic

'Diwali Offer' Stocks by Anil Singhvi: These 2 largecap, 1 smallcap scrips can give up to 70% return - Check targets

'Diwali Offer' Stocks by Anil Singhvi: These 2 largecap, 1 smallcap scrips can give up to 70% return - Check targets

Thu, Oct 31, 2024

'Diwali Offer' Stocks by Anil Singhvi: Stock markets have been very volatile in last one month. Benchmark equity indices Sensex and Nifty fell in early trade even Thursday i.e. October 31, 2024. Amid this, investors are looking for stocks that can offer good return in long term.

Cipla Q2 earnings preview: Margins under pressure as US, domestic sales outlook remains modest

Cipla Q2 earnings preview: Margins under pressure as US, domestic sales outlook remains modest

Tue, Oct 29, 2024

Zee Business forecasts indicate a three percent year-on-year revenue increase, with Cipla’s Q2 revenue expected at Rs 6,892 crore, up from Rs 6,678 crore in the same quarter last year

TRENDING NOW

Drug maker Cipla invests Rs 42 crore in digital tech company GoApptiv

Drug maker Cipla invests Rs 42 crore in digital tech company GoApptiv

Fri, Dec 15, 2023

With the fresh investment, Cipla's total stake in GoApptiv will increase to 22.99 per cent on a fully diluted basis.

Seal integrity issue forces Cipla unit to recall one lot of medication in US

Seal integrity issue forces Cipla unit to recall one lot of medication in US

Sun, Dec 10, 2023

An improper seal in the pouch may lead to the leakage of powder blend outside the pouch, resulting in a lower content of medicine inside the pack compared to the label claim and potential underdosing, it added.

Cipla's Reaction to USFDA's Actions on 8th November, WATCH details here

Cipla's Reaction to USFDA's Actions on 8th November, WATCH details here

Fri, Nov 24, 2023

Cipla's clarification on USFDA's action, warning letter was received on 8th November, investigation was conducted on 6-17th February, Cipla's share fell by almost 8% yesterday, know the complete details in this video.

Cipla rebounds after drug maker seeks to allay investors’ concerns on its Pithampur facility

Cipla rebounds after drug maker seeks to allay investors’ concerns on its Pithampur facility

Fri, Nov 24, 2023

Cipla USFDA news: Cipla said there was no new development requiring additional disclosure on the matter. The sharp fall in Cipla shares on Thursday was triggered by concerns about whether the warning letter will impact the company’s existing products, according to analysts.

D-Street Newsmakers: Cipla, Honasa Consumer and OMCs among top stocks that were on investors' radar today

D-Street Newsmakers: Cipla, Honasa Consumer and OMCs among top stocks that were on investors' radar today

Thu, Nov 23, 2023

Shares of the OMC comapnies logged gains as high as 7 per cent as oil prices continued their southward trajectory amid heavy US stockpiles.

Cipla shares trade flat after pharma major's Indore unit gets warning letter from USFDA

Cipla shares trade flat after pharma major's Indore unit gets warning letter from USFDA

Mon, Nov 20, 2023

Cipla Pithampur facility Indore news: Cipla shares edged lower after the Mumbai-based drugmaker's facility in Pithampur, Indore, received a warning letter from the United States Food and Drug Administration (USFDA).

Mazagon Dock Shipbuilders, Cipla, Kalyan Jewellers among stocks to watch on Monday

Mazagon Dock Shipbuilders, Cipla, Kalyan Jewellers among stocks to watch on Monday

Mon, Nov 20, 2023

Stocks to watch today: Nifty settled lower by 0.17 per cent or 33.4 points, while Sensex gave up 187.75 points to close at 65,795.

Cipla's Promoter Shareholding Faces Possible Revamp with Key Changes

Cipla's Promoter Shareholding Faces Possible Revamp with Key Changes

Mon, Nov 13, 2023

Big news related to Cipla Big changes in promoter shareholding possible, may come in passive role #Cipla's promoter management may get big responsibility, Samina Hameed may come in non-executive role, know complete details in this video

Cipla Q2 Results | Drug maker beats Street estimates with 43% jump in net profit

Cipla Q2 Results | Drug maker beats Street estimates with 43% jump in net profit

Fri, Oct 27, 2023

Mumbai-based drug maker Cipla on Friday reported a 43.4 per cent year-on-year increase in consoldiated net profit to Rs 1,130.9 crore for the July-September period, beating analysts' estimates by a huge margin.

Cipla unit's US facility receives 5 observations from American drug regulator; shares fall

Cipla unit's US facility receives 5 observations from American drug regulator; shares fall

Thu, Sep 21, 2023

Cipla shares remained under pressure on Thursday after the US drug regulator issued five observations about a New York-based facility of the company's wholly-owned subsidiary, InvaGen Pharmaceuticals.

Torrent Pharmaceutical in talks with Apollo to borrow up to $1 billion for Cipla bid: Report

Torrent Pharmaceutical in talks with Apollo to borrow up to $1 billion for Cipla bid: Report

Tue, Sep 19, 2023

Torrent has also been in talks with CVC Capital Partners and Bain Capital who might become equity partners in a consortium and contribute as much as a combined $1.5 billion to the deal, sources have said.

Big Update On Cipla Pharma: Bids to buy promoters' shares soon-sources

Big Update On Cipla Pharma: Bids to buy promoters' shares soon-sources

Thu, Sep 14, 2023

Cipla से जुड़ी Big news related to Cipla: Bids to buy promoters' shares will start soon, bids to buy shares possible by the third week of this month.

Cipla subsidiary to acquire South Africa’s Actor Pharma

Cipla subsidiary to acquire South Africa’s Actor Pharma

Tue, Sep 05, 2023

Actor Pharma, founded in 2009, is the 5th largest privately owned over the counter (OTC) player in the South African private market. Cipla said that this is a strategic acquisition undertaken to unlock growth opportunities in the South African pharmaceutical market.

Cipla shares drop after FDA temporarily suspends licence for Patalganga manufacturing facility in Maharashtra

Cipla shares drop after FDA temporarily suspends licence for Patalganga manufacturing facility in Maharashtra

Thu, Aug 17, 2023

The licence for Cipla’s manufacturing plant in Patalganga was suspended for 10 days for not conforming to good manufacturing practices under the Drugs and Cosmetics Act 1940. The order from the Konkan FDA was issued on August 10.

Blackstone likely to acquire promoter stake in Cipla: What is Blackstone? Its history, big acquisitions and controversies

Blackstone likely to acquire promoter stake in Cipla: What is Blackstone? Its history, big acquisitions and controversies

Fri, Aug 04, 2023

According to reports, Blackstone is expected to submit a non-binding bid by next week to acquire the entire promoter stake of 33.47 per cent in Cipla. Blackstone operates across diverse sectors, including real estate, private equity, credit, and infrastructure.

Cipla clarifies on reports of promoters looking to sell part stake

Cipla clarifies on reports of promoters looking to sell part stake

Fri, Jul 28, 2023

Cipla has clarified that the company is not aware of any event that requires disclosure under Listing Regulations.

Cipla shares zoom 14% as company's Q1 PAT jumps 41.34% to Rs 998.07 crore—should you buy, sell, or hold?

Cipla shares zoom 14% as company's Q1 PAT jumps 41.34% to Rs 998.07 crore—should you buy, sell, or hold?

Thu, Jul 27, 2023

Cipla share price NSE, Cipla share price target: Cipla shares zoomed on Thursday, a day after the pharmaceuticals firm reported a 41.34 per cent rise in its consolidated profit after tax at Rs 998.07 crore in the first quarter ended June 30, 2023, driven by good growth across markets, especially India and the US.

Cipla Q1 results: Consolidated PAT up by 41.34% at Rs 998.07 crore

Cipla Q1 results: Consolidated PAT up by 41.34% at Rs 998.07 crore

Wed, Jul 26, 2023

Pharmaceuticals firm Cipla Ltd on Wednesday reported a 41.34 per cent rise in consolidated profit after tax at Rs 998.07 crore in the first quarter ended June 30, 2023, driven by good growth across markets, specially India and the US.

Cipla Q4: Net profit jumps 45% YoY to Rs 526 crore; final dividend of Rs 8.5/share declared

Cipla Q4: Net profit jumps 45% YoY to Rs 526 crore; final dividend of Rs 8.5/share declared

Fri, May 12, 2023

The drug major had reported a profit of Rs 362.07 crore in the year-ago period.

Cipla dividend: Board announces Rs 8.5 dividend

Cipla dividend: Board announces Rs 8.5 dividend

Fri, May 12, 2023

Cipla dividend 2023: Cipla's board on Friday announced a final dividend of Rs 8.50 per equity share of face value of Rs 2 each i.e., a 425 per cent payout for the financial year 2022-23.

Load More

LIVE TV

By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

x